

MAP-curvature: a model-free approach for analysis of dose-finding trials

Linxi Han^a, Qiqi Deng^b, Zhangyi He^{c,1,*}, Feng Yu^{a,*}

^a*School of Mathematics, University of Bristol, Bristol, UK*

^b*Biostatistics, ModernaTX Inc, Cambridge, Connecticut, USA*

^c*Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK*

Abstract

MCP-Mod (Multiple Comparison Procedure-Modelling) is an efficient statistical method for the analysis of Phase II dose-finding trials, although it requires specialised expertise to pre-specify plausible candidate models along with model parameters. This can be problematic given limited knowledge of the agent/compound being studied. Misspecification of candidate models and model parameters can severely degrade its performance. To circumvent this challenge, in this work, we introduce MAP-curvature, a Bayesian model-free approach for the detection of the dose-response signal in Phase II dose-finding trials. MAP-curvature is built upon a Bayesian hierarchical method incorporating information about the total curvature of the dose-response curve. Through extensive simulations, we show that MAP-curvature has comparable performance to MCP-Mod if the true underlying dose-response model is included in the candidate model set of MCP-Mod. Otherwise, MAP-curvature can achieve performance superior to that of MCP-Mod, especially when the true dose-response model drastically deviates from candidate models in MCP-Mod.

Keywords: Dose finding, Dose-response signal detection, Minimum effective dose estimation, Model-free approach, Bayesian hierarchical model, Curvature prior

1. Introduction

Characterising the dose-response relationship and finding the right dose are important but challenging in the pharmaceutical drug development process. Nearly half of all failures in Phase III trials result in part from a lack of understanding of the dose-response relationship in Phase II

*Corresponding author.

Email addresses: z.he@beatson.gla.ac.uk (Zhangyi He), feng.yu@bristol.ac.uk (Feng Yu)

¹Present address: Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK

5 trials (Sacks et al., 2014). Over the last decade, the Multiple Comparison Procedure-Modelling
6 (MCP-Mod) method, developed by Bretz et al. (2005), has been increasingly popular for Phase
7 II trials as it can provide superior statistical evidence for dose selection.

8 MCP-Mod is a two-step approach that combines MCP principles and modelling techniques.
9 In the first MCP step, it establishes a dose-response signal (Proof of Concept, PoC). In the
10 second Mod step, it estimates the dose-response curve and target doses of interest. It overcomes
11 shortcomings of traditional approaches for dose-finding studies (see *e.g.*, Ting, 2006, for an
12 excellent introduction). MCP-Mod requires the pre-specification of plausible candidate models
13 and model parameters to capture model uncertainty, which however is mainly based on the
14 limited knowledge of the agent/compound being studied, if it is available at all (Chen & Liu,
15 2020). Misspecification of candidate models and model parameters in MCP-Mod may cause
16 a loss in power and unreliable model selection (see Saha & Brannath, 2019, and references
17 therein).

18 Motivated by these shortcomings, in this work, we develop a model-free Bayesian approach
19 for the detection of the dose-response trend and estimation of the dose-response relationship
20 in Phase II trials. We introduce a novel Bayesian hierarchical method incorporating the total
21 (in the L^2 sense) curvature of the dose-response curve as a prior parameter. Our approach
22 avoids the requirement of a set of pre-specified candidate models. The responses at the given
23 set of doses are estimated through maximum *a posteriori* (MAP), with which we construct a
24 test statistic to establish PoC through simulations. We can then estimate the dose-response
25 relationship using simple interpolation.

26 The remainder of this work is organised as follows. In Section 2, we describe in detail our
27 MAP approach with a curvature prior, abbreviated MAP-curvature. In Section 3, we assess the
28 operating characteristics of MAP-curvature through simulations, and compare its performance
29 to that of MCP-Mod. We present concluding remarks and future directions in Section 4.

30 **2. Methods**

31 We consider a trial with a total of $M + 1$ distinct doses x_0, x_1, \dots, x_M , where x_0 represents
32 placebo. Let N_i be the number of patients in dose group i . We assume the true dose response
33 function is $f(x)$ at dose x . We assume $f(x)$ is defined on the interval $[0, 1]$ in what follows

34 unless otherwise specified. For $i = 0, 1, \dots, M$ and $j = 1, 2, \dots, N_i$, we let Y_{ij} be the response
35 observed for patient j allocated to dose x_i . We assume

$$Y_{ij} = \mu_i + \epsilon_{ij}, \quad (1)$$

36 where $\mu_i = f(x_i)$ denotes the mean response at dose x_i , and $\epsilon_{ij} \stackrel{iid}{\sim} N(0, \sigma^2)$ denotes the error
37 term for patient j in dose group i . As in MCP-Mod (Bretz et al., 2005), we assume σ is known.
38 Detailed discussion of the assumption on the standard deviation σ can be found in Fleischer
39 et al. (2022).

40 In MCP-Mod, a set of plausible candidate model curves are specified. This constrains the
41 possible set of dose-response curves. However, with limited knowledge of the agent/compounds
42 in the trial, it is possible to mis-specify this candidate set of models. The procedure for specifying
43 models is also somewhat cumbersome. We would like to avoid the pre-specification of possible
44 models beforehand, but still want to impose a degree of smoothness to the dose-response curve.
45 To this end, we introduce the L^2 -total curvature

$$Sf = \left(\int_{x_0}^{x_M} f''(x)^2 dx \right)^{1/2}$$

46 to measure how far the dose-response curve $f(x)$ is from being a straight line. We will impose a
47 half-normal $HN(\gamma^2)$ prior on Sf to give low prior probabilities to the dose-response that is very
48 curved, where the standard deviation γ controls the trade-off between the L^2 -total curvature of
49 $f(x)$ and fidelity to data \mathbf{Y} . Given the dose-response function $f(x)$ being available at $M + 1$
50 distinct doses, for $i = 1, 2, \dots, M - 1$, we have

$$f''(x_i) \approx 2 \left(\frac{\mu_{i+1} - \mu_i}{(x_{i+1} - x_i)(x_{i+1} - x_{i-1})} - \frac{\mu_i - \mu_{i-1}}{(x_i - x_{i-1})(x_{i+1} - x_{i-1})} \right)$$

51 through the second-order central difference scheme (Burden et al., 2015), therefore the L^2 -total
52 curvature Sf being approximated through numerical integration with

$$S_{\mu} = 2 \left(\sum_{i=1}^{M-1} \left(\frac{\mu_{i+1} - \mu_i}{(x_{i+1} - x_i)(x_{i+1} - x_{i-1})} - \frac{\mu_i - \mu_{i-1}}{(x_i - x_{i-1})(x_{i+1} - x_{i-1})} \right)^2 \Delta x_i \right)^{1/2},$$

53 where $\Delta x_i = (x_{i+1} - x_{i-1})/2$ for $i = 2, 3, \dots, M - 2$ with $\Delta x_1 = (x_2 + x_1)/2 - x_0$ and $\Delta x_{M-1} =$

54 $x_M - (x_{M-1} + x_{M-2})/2$.

55 We let

$$\mathbf{Y} = \{Y_{ij}, i = 0, 1, \dots, M, j = 1, 2, \dots, N_i\}$$

56 and define our Bayesian hierarchical model to be

$$p(\boldsymbol{\mu}, \gamma | \mathbf{Y}) \propto p(\boldsymbol{\mu}, \gamma)p(\mathbf{Y} | \boldsymbol{\mu}), \quad (2)$$

57 where the prior

$$p(\boldsymbol{\mu}, \gamma) = p(\gamma) \prod_{i=0}^M p(\mu_i)p(S_{\boldsymbol{\mu}} | \gamma)$$

58 with

$$S_{\boldsymbol{\mu}} | \gamma \sim HN(\gamma^2), \gamma \sim HN(\tau^2), \mu_i \stackrel{iid}{\sim} U(0, 1) \text{ for } i = 0, 1, \dots, M,$$

59 and the likelihood

$$p(\mathbf{Y} | \boldsymbol{\mu}) = \prod_{i=0}^M \prod_{j=1}^{N_i} p(Y_{ij} | \mu_i).$$

60 Suppose the standard deviation τ in the hyperprior for γ is pre-specified. The MAP estimates of
61 all parameters in the model defined in Eq. (2) can be obtained by maximising the corresponding
62 log-likelihood

$$\hat{\boldsymbol{\mu}}, \hat{\gamma} = \arg \max_{\boldsymbol{\mu}, \gamma} \left\{ - \sum_{i=0}^M \sum_{j=1}^{N_i} \left(\frac{Y_{ij} - \mu_i}{\sigma} \right)^2 - \log \gamma^2 - \left(\frac{S_{\boldsymbol{\mu}}}{\gamma} \right)^2 - \left(\frac{\gamma}{\tau} \right)^2 \right\}$$

63 through a numerical optimisation algorithm like the Broyden–Fletcher–Goldfarb–Shanno (BFGS)
64 method and its variants (see, *e.g.*, Nocedal & Wright, 1999, for more details).

65 To establish PoC, we propose a test statistic

$$T = \max\{\hat{\mu}_1 - \hat{\mu}_0, \hat{\mu}_2 - \hat{\mu}_0, \dots, \hat{\mu}_M - \hat{\mu}_0\}$$

66 with hypotheses

$$H_0 : \hat{\mu}_0 = \hat{\mu}_1 = \dots = \hat{\mu}_M$$

$$H_1 : \max\{\hat{\mu}_1, \hat{\mu}_2, \dots, \hat{\mu}_M\} > \hat{\mu}_0.$$

67 We define a significance level α for a dose-response signal, such that the corresponding critical
68 value c satisfies

$$\mathbb{P}(T > c \mid H_0) < \alpha.$$

69 For a given α , we compute the critical value c via simulation

$$\mathbb{P}(T > c \mid H_0) \approx \frac{1}{R} \sum_{r=1}^R \mathbb{1}_{\{T^{(r)} > c\}},$$

70 where $T^{(r)}$ is the test statistic computed from the data $\mathbf{Y}^{(r)}$ simulated under the null hypothesis
71 H_0 , R is the total number of replicates, and $\mathbb{1}_A$ is the indicator function equal to 1 if condition
72 A holds and 0 otherwise.

73 Finally, the mean response estimates $\hat{\boldsymbol{\mu}}$ can be linearly interpolated (or using a more sophis-
74 ticated interpolation scheme) to obtain an estimate of the dose-response curve $f(x)$, which will
75 also yield an estimate of the target dose of interest. In this work, we only perform simple linear
76 interpolation as we shall focus on the PoC stage of dose-finding trials.

77 3. Simulations

78 In this section, we assess the performance of MAP-curvature, in terms of power to detect
79 dose-response signals as well as estimates of the dose-response curve and target doses of interest.
80 We compare MAP-curvature to MCP-Mod.

81 3.1. Simulation settings

82 We simulate randomised, double-blind, parallel-group trials with patients being equally
83 allocated to placebo (0) or one of four active doses (0.15, 0.50, 0.80 and 1). We take the
84 placebo response rate to be 0% and the maximum treatment effect to be 50%, respectively. We
85 vary the sample size per dose group in $\{10, 20, 30, 40, 50, 60\}$. We choose one of 12 common
86 dose-response shapes to be the true dose-response model. These models are plotted in Figure 1,
87 with corresponding parameters summarised in Supplemental Material, Table S1. We simulate
88 each patient's response according to Eq. (1) with a standard deviation of $\sigma = 1$. For each of 72
89 combinations of parameters, consisting of sample size and dose-response shape, we run 10,000
90 simulated trials.




Figure 1: Dose-response shapes selected for the true dose-response model.

91 For each simulated trial, we run MAP-curvature to establish PoC and find the target doses
92 of interest with a standard deviation of $\tau \in \{1, 3, 5\}$ for the hyperprior $HN(\tau^2)$. To bench-
93 mark MAP-curvature against MCP-Mod, we run MCP-Mod for each simulated trial using the
94 **DoseFinding** package (version 1.0-2) in R, where we specify a fixed set of candidate models made
95 up of linear, emax1, emax2, exponential1, quadratic and logistic1 (top six figures of Figure 1).

96 *3.2. Simulation results*

97 To compare the performance of MAP-curvature and MCP-Mod, in Figure 2, we plot receiver
98 operating characteristic (ROC) curves for all true dose-response models for sample size 40. The
99 ROC curve is produced by plotting the true positive rate against the false positive rate across a
100 range of critical values. The closer the ROC curve approaches the top left corner, the better the
101 method performs overall. ROC curves for all other sample sizes are illustrated in Supplemental
102 Material, Figures S1-S5. We also summarise their powers at 5% and 10% type I error rates in
103 Supplemental Material, Table S2 and S3, respectively.

104 We see from Figure 2 that MAP-curvature has better performance when the true dose-
105 response relationship is not dramatically curved, e.g. linear, emax1, logistic1, logistic2 and
106 sigEmax, achieving over 80% power at 5% type I error rate. Choosing an appropriate τ can
107 further improve the performance of MAP-curvature. More specifically, MAP-curvature achieves
108 better performance with a larger τ for the true dose-response curve that is more curved, e.g.
109 quadratic1 and beta models. Otherwise, e.g. in logistic1 and power models, a smaller τ performs
110 better. How to select an appropriate τ in practice will be discussed in Section 4.

111 To compare the performance of MAP-curvature and MCP-Mod, we divide into two cases:

- 112 1. the true dose-response curve is one of the candidate models in MCP-Mod,
- 113 2. the true dose-response curve is not one of the candidate models in MCP-Mod.

114 Figures 2(a-f) compare the performance of MAP-curvature and MCP-Mod for the first case,
115 which is a fairly rare situation in practice. The resulting ROC curves are in favour of MCP-
116 Mod as expected, but MAP-curvature with $\tau = 3$ achieves comparable performance. We note
117 that for the true dose-response curve that is not dramatically curved, e.g. linear, emax1 and
118 logistic1, $\tau = 1$ yields better performance than when $\tau = 3$, giving a power gain of around 2-9%
119 for MAP-curvature with respect to MCP-Mod at 5% type I error rate.

120 Figures 2(g-l) compare the performance of MAP-curvature and MCP-Mod for the second
121 case. This is the situation we expect to encounter in practice. We see that with $\tau = 3$, MAP-
122 curvature uniformly outperforms MCP-Mod, especially when the true dose-response model dras-
123 tically deviates from the candidate model set in MCP-Mod such as sigEmax and beta mod-
124 els. In the latter case, MAP-curvature has a power gain of approximately 5-10% compared to
125 MCP-Mod at a type I error rate of 5%. Some true dose-response models such as exponential2,




Figure 2: ROC curves of MAP-curvature and MCP-Mod across different true dose-response models with the sample size of 40 patients per arm. The ROC curves of MCP-Mod in (a)-(f) are produced with the true dose-response model not included in the candidate model set, and the ROC curves of MCP-Mod in (g)-(l) are produced with the true dose-response model not included in the candidate model set.

126 quadratic2 and power models, are captured by the candidate model set of MCP-Mod sufficiently
 127 well that the performance of MAP-curvature and MCP-Mod is similar. With an appropriate τ ,
 128 however, MAP-curvature is still able to achieve significantly better performance, e.g. a power
 129 gained by around 2-3% for MAP-curvature over MCP-Mod at 5% type I error rate.

130 We also assess and compare the performance in estimating the dose-response curve and tar-

131 get doses of interest, known as the minimum effective dose (MED). See Supplemental Material,
132 Figures S6-S11 for the dose-response curves estimated using MAP-curvature and MCP-Mod
133 for various true dose-response models and sample sizes. The corresponding results for MED
134 estimation are summarised in Supplemental Material, Table S4.

135 4. Discussion

136 In this work, we have introduced MAP-curvature, a novel Bayesian approach for establish-
137 ing PoC and estimating the dose-response curve alongside target doses of interest in Phase II
138 trials. MAP-curvature is “model-free”, in the sense that it does not require pre-specification of
139 candidate model curves, which can influence the performance of MCP-Mod. It is built upon
140 a Bayesian hierarchical model incorporating prior information on the L^2 -total curvature of the
141 dose-response curve. Through extensive simulations, we have shown that MAP-curvature has
142 performance comparable to that of MCP-Mod in establishing PoC and estimating MED when
143 the candidate model set of MCP-Mod includes the true dose-response model. When the true
144 dose-response model deviates from the candidate model set of MCP-Mod, we have shown that
145 MAP-curvature outperforms MCP-Mod.

146 To achieve optimal performance, MCP-Mod requires specialised expertise to pre-specify
147 plausible candidate models and model parameters, but the knowledge of the agent/compounds
148 being studied is commonly limited. Compared to MCP-Mod, the only requirement for pre-
149 specification in MAP-curvature is the standard deviation τ for the hyperprior $\gamma \sim HN(\tau^2)$,
150 which encodes prior knowledge of how far the dose-response curve is from a straight line. Based
151 on additional simulations with varying values of the standard deviation τ (see Supplemental
152 Material, Figure S12 and Table S5), we recommend choosing

- 153 1. $\tau \in [2, 4]$ if our prior knowledge is poor,
- 154 2. $\tau < 2$ if we are confident that the curvature of the dose-response curve is weak,
- 155 3. $\tau > 4$ if we are confident that the curvature of the dose-response curve is strong.

156 A number of relevant issues for MAP-curvature deserve further research. The current version
157 of MAP-curvature is limited to analysing Phase II dose-finding trials with continuous endpoints,
158 *i.e.*, a single normally distributed homoscedastic response measured at the end of the trial for
159 each patient. To expand the applicability of MAP-curvature, extensions to other common

160 types of endpoints (*e.g.*, binary, counts and survival endpoints) and trials (*e.g.*, longitudinal
161 dose-finding trials) require further investigation. Other directions of future research include the
162 investigation of trial designs tailored to MAP-curvature and development of statistical software
163 implementing MAP-curvature.

164 **Acknowledgements**

165 This work was carried out using the computational facilities of the Advanced Computing
166 Research Centre, University of Bristol - <http://www.bristol.ac.uk/acrc/>.

167 **Disclosure Statement**

168 The authors report there are no competing interests to declare.

169 **Disclaimer**

170 The opinions expressed in this paper are solely those of the authors and not those of their
171 affiliations. The authors' affiliations do not guarantee the accuracy or reliability of the infor-
172 mation provided herein.

173 **References**

- 174 Bretz, F., Pinheiro, J. C., & Branson, M. (2005). Combining multiple comparisons and modeling
175 techniques in dose-response studies. *Biometrics*, *61*, 738–748.
- 176 Burden, R. L., Faires, J. D., & Burden, A. M. (2015). *Numerical Analysis*. Boston: Cengage
177 Learning.
- 178 Chen, J., & Liu, T. (2020). Statistical considerations on implementing the MCP-Mod method
179 for binary endpoints in clinical trials. *Contemporary Clinical Trials Communications*, *19*,
180 100641.
- 181 Fleischer, F., Bossert, S., Deng, Q., Loley, C., & Gierse, J. (2022). Bayesian MCPMod. *Phar-
182 maceutical Statistics*, *21*, 654–670.
- 183 Nocedal, J., & Wright, S. J. (1999). *Numerical Optimization*. New York: Springer.

- 184 Sacks, L. V., Shamsuddin, H. H., Yasinskaya, Y. I., Bouri, K., Lanthier, M. L. et al. (2014).
185 Scientific and regulatory reasons for delay and denial of FDA approval of initial applications
186 for new drugs, 2000-2012. *JAMA*, *311*, 378–384.
- 187 Saha, S., & Brannath, W. (2019). Comparison of different approaches for dose response analysis.
188 *Biometrical Journal*, *61*, 83–100.
- 189 Ting, N. (2006). *Dose Finding in Drug Development*. New York: Springer.